Teleflex Incorporated Stock News

Las Vegas, USA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Spirometers Market to Grow at a Significant CAGR of 9.30% by 2026, Examines DelveInsight The demand for Spirometers is primarily attributed to the global prevalence of respiratory disorders like asthma, COPD, cystic fibrosis, the growing aging population, and technological progress. All these factors will directly lead to a surge in the Spirometers market. DelveInsight''s Spirometers Market Insights and Forecast report provides the current and forecast Spirometers Market, upcoming innovation in the devices, individual market shares, challenges, drivers, and barriers, market trends, and key competitors in the Spirometers Market. Some of the essential factors from the Spirometers Market report: As per DelveInsight analysis, in terms of revenue share, North America is predicted to register the fastest growth and occupy the largest share in the Spirometers market. Key Spirometers companies proactively developing novel devices include names such as Hill Rom, Inc., Teleflex Incorporated, Vyaire Medical Inc., Fukuda Sangyo Co., Ltd., Chest M.I., Inc., Midmark Corporation, Futuremed USA, COSMED, MGC Diagnostics Corporation, NDD Medical Technologies, Schiller AG, MIR, Sibelmed, Smiths Medical PLC, Vitalograph, Jones Medical Instrument Company, Contec Medical Systems Co., Ltd., Medikro Oy, Clarity Medical, KoKo PFT and others.

Teleflex (NYSE:TFX) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $3.53 (+8.6% Y/Y) and the consensus…

Teleflex Incorporated with ticker code (TFX) now have 9 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 455 and 325 and has a mean target at 408.56. Given that the stocks previous close was at 317.99 this would imply there is a potential upside of 28.5%. The day 50 moving average is 321.25 while the 200 day moving average is 363.63. The company has a market cap of $14,793m. Company Website: https://www.teleflex.com [stock_market_widget type="chart" template="basic" color="green" assets=TFX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $19,006m based on the market concensus. Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

WAYNE, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 24, 2022.

WAYNE, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter and full year 2021 financial results and provide an operational

Dublin, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The "Urinary Incontinence Market by Product, Incontinence Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The global urinary incontinence market was valued at $10,124.33 million in 2020, and is projected to reach $19,341.15 million by 2030, registering a CAGR of 6.8% from 2021 to 2030. The involuntary flow of urine due to a loss of bladder control is known as urinary incontinence. Urinary incontinence devices aid in collecting and holding urine; such devices help in managing urinary incontinence effectively. People undergoing urinary incontinence suffer from urine leakage that cannot be controlled. Patients suffering from severe urinary incontinence are recommended surgical treatment that incorporates devices such as urinary catheter, vaginal slings, electrical stimulation devices, and artificial urinary sphincters. Among the aforementioned incontinent devices, the most evidently used devices include indwelling catheters, external collecting systems, urine drainage bags, and catheters for intermittent catheterization (IC).

Las Vegas, USA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Vascular Access Devices Market is Expected to Surge at a Significant CAGR of 6.64% and is also Contemplated to Reach Upto USD 6.13 Billion by 2026, Estimates DelveInsight The Vascular Access Device market is anticipated to grow tremendously in the coming years due to many factors which include the rising prevalence of end-stage renal diseases and the rising number of vascular access surgeries, these are striving the Vascular Access Devices demand, thus driving the growth of Vascular Access Device market. DelveInsight''s Vascular Access Devices Market Insights and Forecast report provides the current and forecast Vascular Access Devices, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Vascular Access Devices. Some of the essential takeaways from the Vascular Access Devices Market report: According to DelveInsight analysis, North America is expected to dominate the overall Vascular Access Devices Market during the forecast period.

DUBLIN , Jan. 25, 2022 /PRNewswire/ -- The "Urinary Incontinence Market by Product, Incontinence Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com''s offering. The global urinary incontinence market was valued at $10,124.33 million in 2020, and is projected to reach $19,341.15 million by 2030, registering a CAGR of 6.8% from 2021 to 2030. The involuntary flow of urine due to a loss of bladder control is known as urinary incontinence. Urinary incontinence devices aid in collecting and holding urine; such devices help in managing urinary incontinence effectively. People undergoing urinary incontinence suffer from urine leakage that cannot be controlled. Patients suffering from severe urinary incontinence are recommended surgical treatment that incorporates devices such as urinary catheter, vaginal slings, electrical stimulation devices, and artificial urinary sphincters. Among the aforementioned incontinent devices, the most evidently used devices include indwelling catheters, external collecting systems, urine drainage bags, and catheters for intermittent catheterization (IC).

Los Angeles, USA, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Mechanical Circulatory Support Devices Market is Anticipated to Grow at a Significant CAGR of 9.43% and is Expected to Expand Up to USD 3.88 Billion by 2026, Analyzes DelveInsight The Mechanical Circulatory Support Devices market is contemplated to rise in the coming years owing to various factors such as rising incidence of cardiovascular disorders and the growing incidence of heart failure leading to an increase in the demand for Mechanical Circulatory Support Devices, thus driving the growth of Mechanical Circulatory Support Devices market. DelveInsight''s Mechanical Circulatory Support Devices Market Insights and Forecast report provides the current and forecast Mechanical Circulatory Support Devices, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Mechanical Circulatory Support Devices. Some of the essential takeaways from the Mechanical Circulatory Support Devices Market report: According to DelveInsight analysis, North America is expected to dominate the overall Mechanical Circulatory Support Devices market during the forecast period.

WAYNE, Pa., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 40th Annual J.P. Morgan Healthcare Conference on

Retail tax loss selling and institutional portfolio window dressing can artificially depress underperforming stocks in the final trading days of the calendar year. Buying a basket of underperformers,

Shares of Teleflex Incorporated (NYSE:TFX) have received a consensus rating of Buy from the twelve analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price []

Respiratory Devices Market report includes major data, present request trends, terrain, technological invention, forthcoming technologies and the specialized progress in the affiliated assiduity. Respiratory Devices Market offers complete, complete report delivering request exploration data that''s applicable for new request entrants

The global Clot Management Devices market was valued at 1242.65 Million USD in 2020 and will grow with a CAGR of 3.89% from 2021 to 2027. The key variables driving the development of clot management devices market are rising commonness

Teleflex Incorporated found using ticker (TFX) have now 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 486 and 415 calculating the mean target price we have 462.55. Given that the stocks previous close was at 318 this would indicate that there is a potential upside of 45.5%. The 50 day MA is 338.97 and the 200 moving average now moves to 384.92. The market capitalisation for the company is $15,025m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="TFX" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.